Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries

Mostrar otras versiones (1)

OBJECTIVES: The aim of this pooled analysis of the TOZURA study programme was to evaluate the efficacy and safety of subcutaneous tocilizumab (TCZ-SC) as monotherapy or in combination with conventional synthetic DMARDs (csDMARDs) in patients with moderate to severe RA who had an inadequate response...

Descripción completa

Detalles Bibliográficos
Autores principales: Choy, Ernest, Caporali, Roberto, Xavier, Ricardo, Fautrel, Bruno, Sanmarti, Raimón, Bao, Min, Bernasconi, Corrado, Pethö-Schramm, Attila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850727/
https://www.ncbi.nlm.nih.gov/pubmed/29244149
http://dx.doi.org/10.1093/rheumatology/kex443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850727/
https://www.ncbi.nlm.nih.gov/pubmed/29244149
http://dx.doi.org/10.1093/rheumatology/kex443

Ejemplares similares